Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction

The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone. Platelets express several members of the MAPK signalling cascade including MEK1 and MEK2 and ERK1 and ERK2 but t...

Descripción completa

Detalles Bibliográficos
Autores principales: Unsworth, Amanda J., Bye, Alexander P., Kriek, Neline, Sage, Tanya, Osborne, Ashley A., Donaghy, Dillon, Gibbins, Jonathan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594423/
https://www.ncbi.nlm.nih.gov/pubmed/30252580
http://dx.doi.org/10.1080/09537104.2018.1514107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594423/
https://www.ncbi.nlm.nih.gov/pubmed/30252580
http://dx.doi.org/10.1080/09537104.2018.1514107

Ejemplares similares